Population Pharmacokinetic –Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis
ConclusionThe PopPK/PD models showed numerically greater reductions in DAS28-CRP and ANC with sarilumab 200 Â mg every 2Â weeks than with 150Â mg every 2Â weeks. There was no clinically meaningful influence of investigated covariates. These data contribute to the totality of evidence that supports a sarilumab subcutaneous starting dose of 200Â mg every 2Â weeks, with a subsequent reduction to 150Â mg ever y 2Â weeks in the event of laboratory abnormalities such as neutropenia.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Drugs & Pharmacology | Laboratory Medicine | Methotrexate | Rheumatoid Arthritis | Rheumatology | Study